MRI-guided adaptive radiotherapy for large brain metastases
Displacement and Deformation Analysis of Adaptive Radiotherapy Based on MR-Linac for Large Brain Metastases
This study is testing how well MRI-guided radiation therapy works for treating large brain tumors in lung cancer patients by looking at how these tumors change during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06405256 on ClinicalTrials.gov |
What this trial studies
This ambispective cohort study evaluates the displacement and deformation of large brain metastases treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART). Patients with pathologically confirmed lung cancer and brain metastases of 2cm or larger will undergo treatment using Unity MR-linac, where gross tumor volume and organs at risk will be re-delineated for each imaging set. The study aims to analyze how these tumors change during treatment to improve therapeutic outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with pathologically confirmed lung cancer and brain metastases measuring 2cm or larger.
Not a fit: Patients with anticipated survival of less than 3 months or those unable to tolerate the supine position for treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the precision of radiotherapy for patients with large brain metastases, potentially leading to better treatment outcomes.
How similar studies have performed: While MRI-guided radiotherapy is an emerging field, this specific approach to large brain metastases is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years; KPS score ≥ 60. 2. pathologically confirmed lung cancer. 3. diagnosed with brain metastases by enhanced MRI. 4. BM volume ≥ 2cm. 5. Anticipated time to survival\>3 months. 6. Treated with Unity MR-linac. 7. Good compliance; Able to stay still in supine position for 45 minutes and above. Exclusion Criteria: 1. Fail to complete radiotherapy as planned; Anticipated time to survival less than 3 months. 2. Suffer from severe back pain in supine position, unable to receive Unity MR-linac. 3. Suffer from severe claustrophobia. 4. Incomplete pre-Unity image data.
Where this trial is running
Beijing
- Chinese Academy of Medical Science and Peking Union Medical College — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Nan Bi, MD — Chinese Academy of Medical Sciences and Peking Union Medical College
- Study coordinator: Nan Bi, MD
- Email: binan_email@163.com
- Phone: 8601087788799
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.